SCHEMBL3460690

SCHEMBL3460690

Cc1cc(C)n2nccc2n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 2/20 0.48
KDM4E B2RXH2 8/20 0.47
NPC1 O15118 7/20 0.47
RAB9A P51151 7/20 0.47
ALDH1A1 P00352 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
PDE10A Q9Y233 1/20 0.46
MAPT P10636 2/20 0.44
HPGD P15428 1/20 0.42
HCRTR1 O43613 1/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
UBE2M P61081 1/20 0.40
DCUN1D1 Q96GG9 1/20 0.40
RECQL P46063 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13073900 0.80 PDE10A (0.43) PIK3CGALDH1A1PDE10A
SCHEMBL9300367 0.80 PDE10A (0.43) PIK3CGALDH1A1PDE10A
SCHEMBL29344715 0.80 PDE10A (0.67) NPC1RAB9APDE10A
SCHEMBL20664459 0.80 PDE10A (0.43) KDM4ENPC1RAB9APDE10A
SCHEMBL4431791 0.80 ALDH1A1 (0.50) PIK3CGKDM4ENPC1RAB9AALDH1A1
SCHEMBL4102510 0.80 PDE10A (0.43) PIK3CGKDM4ENPC1RAB9AALDH1A1
SCHEMBL10408224 0.80 PDE10A (0.43) PIK3CGKDM4ENPC1RAB9AALDH1A1
SCHEMBL9301157 0.80 PDE10A (0.43) PIK3CGKDM4ENPC1RAB9AALDH1A1
SCHEMBL20406305 0.80 PDE10A (0.43) PIK3CGKDM4ENPC1RAB9AALDH1A1
SCHEMBL659433 0.80 PDE10A (0.67) PIK3CGKDM4ENPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109712-A1 RIFAMYCINS FOR NONTUBERCULOUS MYCOBACTERIA UNIV MINNESOTA (US) 2026-04-23 US disclosed
EP-4598930-A1 RIFAMYCINS FOR NONTUBERCULOUS MYCOBACTERIA Regents of the University of Minnesota (US) 2025-08-13 EP disclosed
EP-4107159-B1 5-(3-(ETHYLSULFONYL)PYRIDIN-2-YL)-PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS PESTICIDE AND INSECTICIDE AGENTS FOR CROP PROTECTION PI INDUSTRIES LTD (IN) 2024-04-17 EP disclosed
WO-2024076693-A1 RIFAMYCINS FOR NONTUBERCULOUS MYCOBACTERIA REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2024-04-11 WO disclosed
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-12-13 US disclosed
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS VALO EARLY DISCOVERY, INC. 2021-10-21 US disclosed
CN-107208279-B Etching solution, replenishment solution, and method for forming copper wiring MEC股份有限公司 2021-03-26 CN disclosed
US-20200239439-A1 HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) 2020-07-30 US disclosed
WO-2020065614-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-04-02 WO disclosed
WO-2019148005-A1 INHIBITORS OF CBL-B AND METHODS OF USE THEREOF NURIX THERAPEUTICS, INC. (US) 2019-08-01 WO disclosed
US-5635495-A ANTIARTHRITIC AGENTS TREATING BONE DISORDER, OSTEOPOROSIS; CALCIUM CHANNEL BLOCKERS THE UPJOHN COMPANY (US) 1997-06-03 US disclosed
EP-0593575-B1 PYRAZOLOPYRIMIDINE AND PYRIMIDINYL BISPHOSPHONIC ESTERS AS ANTI-INFLAMMATORIES UPJOHN CO (US) 1997-05-07 EP disclosed
CN-1119941-A Use of purimifdinyl bisphophonic esters for the preparation of a medicament for treating of inflammatin UPJOHN CO (US) 1996-04-10 CN disclosed
EP-0663919-A1 PYRIMIDINE BISPHOSPHONATE ESTERS AS ANTI-INFLAMATORIES PHARMACIA & UPJOHN COMPANY (US) 1995-07-26 EP disclosed
US-5397774-A Pyrazolopyrimidine and pyrimidinyl bisphosphonic esters as anti-inflammatories THE UPJOHN COMPANY (US) 1995-03-14 US disclosed
WO-1994009017-A1 PYRIMIDINE BISPHOSPHONATE ESTERS AND (ALKOXYMETHYLPHOSPHINYL)ALKYL PHOSPHONIC ACIDS AS ANTI-INFLAMMATORIES THE UPJOHN COMPANY (US) 1994-04-28 WO disclosed
EP-0593575-A1 PYRAZOLOPYRIMIDINE AND PYRIMIDINYL BISPHOSPHONIC ESTERS AS ANTI-INFLAMMATORIES. UPJOHN CO (US) 1994-04-27 EP disclosed
WO-1993001198-A1 PYRAZOLOPYRIMIDINE AND PYRIMIDINYL BISPHOSPHONIC ESTERS AS ANTI-INFLAMMATORIES THE UPJOHN COMPANY (US) 1993-01-21 WO disclosed
EP-0521622-A1 Pyrazolopyrimidine and pyrimidinyl bisphosphonic esters as anti-inflammatories THE UPJOHN COMPANY (US) 1993-01-07 EP disclosed
US-4093617-A ENZYME INHIBITORS ICN PHARMACEUTICALS, INC. (US) 1978-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 PIK3CG 2487/4885KDM4E 403/4885NPC1 3743/4885
US-20260109712-A1 RIFAMYCINS FOR NONTUBERCULOUS MYCOBACTERIA RIF1, MRPL21, NRDC PIK3CG 3730/4885KDM4E 4476/4885NPC1 94/4885
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS USP28, USP25, USP24 PIK3CG 2487/4885KDM4E 403/4885NPC1 3743/4885
US-20200239439-A1 HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME CXCR4, CXCL12, CXCR1 PIK3CG 463/4885KDM4E 4466/4885NPC1 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.